Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash & Equivalents (2016 - 2025)

Guided Therapeutics' Cash & Equivalents history spans 16 years, with the latest figure at $87000.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 55.15% year-over-year to $87000.0; the TTM value through Sep 2025 reached $87000.0, down 55.15%, while the annual FY2024 figure was $388000.0, 34.35% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $87000.0 at Guided Therapeutics, down from $185000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.7 million in Q3 2022 and bottomed at $87000.0 in Q3 2025.
  • The 5-year median for Cash & Equivalents is $591000.0 (2023), against an average of $828421.1.
  • The largest annual shift saw Cash & Equivalents skyrocketed 5838.1% in 2021 before it tumbled 79.75% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $643000.0 in 2021, then soared by 259.72% to $2.3 million in 2022, then plummeted by 74.45% to $591000.0 in 2023, then tumbled by 34.35% to $388000.0 in 2024, then tumbled by 77.58% to $87000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Cash & Equivalents are $87000.0 (Q3 2025), $185000.0 (Q2 2025), and $115000.0 (Q1 2025).